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Abstract 
Background: Cytochrome P450 monooxygenase constitutes a significant group of oxidative enzymes that can intro‑
duce an oxygen atom in a high regio‑ and stereo‑selectivity mode. We used the Bacillus megaterium cytochrome P450 
BM3 (CYP450 BM3) and its variants namely mutant 13 (M13) and mutant 15 (M15) for the hydroxylation of diverse 
class of flavonoids.
Results: Among 20 flavonoids, maximum seven flavonoids were hydroxylated by the variants while none of these 
molecules were accepted by CYP450 BM3 in in vitro reaction. Moreover, M13 exhibited higher conversion of sub‑
strates than M15 and CYP450 BM3 enzymes. We found that M13 carried out regiospecific 3ʹ‑hydroxylation reaction 
of naringenin with the highest conversion among all the tested flavonoids. The apparent Km and kcat values of M13 
for naringenin were 446 µM and 1.955 s−1, respectively. In whole‑cell biotransformation experiment with 100 µM of 
naringenin in M9 minimal medium with 2 % glucose in shake flask culture, M13 showed 2.14‑ and 13.96‑folds higher 
conversion yield in comparison with M15 (16.11 %) and wild type (2.47 %). The yield of eriodictyol was 46.95 µM 
[~40.7 mg (13.5 mg/L)] in a 3‑L volume lab scale fermentor at 48 h in the same medium exhibiting approximately 
49.81 % conversion of the substrate. In addition, eriodictyol exhibited higher antibacterial and anticancer potential 
than naringenin, flavanone and hesperetin.
Conclusions: We elucidated that eriodictyol being produced from naringenin using recombinant CYP450 BM3 and 
its variants from B. megaterium, which shows an approach for the production of important hydroxylated compounds 
of various polyphenols that may span pharmaceutical industries.
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Background
Cytochrome P450 enzymes (CYP450s) catalyze diverse 
types of chemical reactions such as hydroxylation, epoxi-
dation, reduction, oxidation, deamination, peroxidation, 
O-demethylation, desulfonation and dehalogenation [1, 
2]. In general, CYP450s introduce an atom of oxygen into 
a substrate and the concomitant reduction of the sec-
ond oxygen atom to water. CYP450s mediated reactions 
offer great potential for the realistic application of regio-
selective and stereo-selective hydroxylation of diverse 
substrates [3–7]. CYP450 BM3 (CYP102A1) from Bacil-
lus megaterium is a self-sufficient fatty acid monooxyge-
nase, which has been studied since last 30 years [8] and 
has emerged as a potent biocatalyst for biotechnological 
application [9]. CYP450 BM3 is a class II P450 enzyme 
that consists of natural fusion between heme-Fe-depend-
ent monooxygenase domain and the electron transfer 
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flavin mononucleotide (FMN)/flavin adenine dinucleo-
tide (FAD) reductase domain in a single continuous 119-
kDa polypeptide. The natural substrates of CYP450 BM3 
are C12–C20 fatty acids that are hydroxylated at very high 
activity at sub-terminal position [10]. Moreover, through 
rational design or directed evolution, protein engineer-
ing of CYP450 BM3 has been carried out to expand the 
substrates flexibility to generate pharmaceutically impor-
tant molecules [11–15]. These recent advances sug-
gest that CYP450 BM3 mutant (M13: R47L/L86I/F87V/
L188Q; M15: R47L/E64G/F87V/E143G/L188Q/E267V) 
can be developed as a biocatalyst for drug discovery and 
synthesis. However, there have been no reports of either 
CYP450 BM3 wild type or mutant M13 and M15 modi-
fying flavonoid groups of compounds to produce diverse 
hydroxylated products.
Flavonoids are one of the most numerous and struc-
turally diverse natural products present in the plant 
kingdom [16]. They are known to have multi-beneficial 
medicinal and chemo-preventive activities in human 
health. Flavonoids have been shown to act as antioxidant 
[17], antibacterial [18], anti-inflammatory [19], hepato-
protective [20], and anticancer properties [21]. However, 
the pharmaceutical application of these compounds is 
limited, because of their low water solubility and insta-
bility. Hydroxylation of the activated or non-activated 
carbon atoms in the flavonoids improves their meta-
bolic stability and enhances the solubility, which greatly 
enhances their biological properties [22]. Some of the 
hydroxylated flavonoids exhibited better antioxidants 
than their parental flavonoids [23], suppression of ultra-
violet (UV)-B induced skin cancer [24] and modulates 
multidrug resistance transporters and induces apoptosis 
[25]. Naringenin, a typical flavanone that is also known 
as (2S)-naringenin or 4′,5,7-trihydroxyflavanone, has a 
wide spectrum of pharmacological activities, including 
immunomodulatory and cellular antioxidant [26], anti-
flammatory and anti-carcinogenic effects [27]. Moreover, 
it was also found to be beneficial for preventing the onset 
of chronic diseases like diabetes, obesity, and hyperten-
sion [28, 29]. O-Glycosylation and O-methylation are 
major modification reactions in enzymatic synthesis as 
well as biotransformation of naringenin [30–32]. But, 
the hydroxylation of flavonoids including naringenin has 
not been well studied. The recombinant S. cerevisiae cells 
overexpressing PcCYP65a2 derived from the white-rot 
fungus Phanerochaete chrysosporium exhibited narin-
genin hydroxylation at 3′-position to yield eriodictyol 
[33]. Flavonoids hydroxylase from Catharanthus roseus 
[34] and Gerbera hybrida [35] have also been charac-
terized; however these studies did not use them as bio-
catalysts, because of difficulty in enzyme expression in a 
heterologous system.
In this study, we identified CYP450 BM3 variants capa-
ble of hydroxylating diverse sets of flavonoids tested 
(Fig.  1). We achieved regiospecific hydroxylation of fla-
vonoids with high bioconversion of naringenin to erio-
dictyol by using one of the variants of CYP450 BM3, 
M13 when expressed in Escherichia coli. The product 
eriodictyol was tested for antibacterial activity against 
Gram-positive organism such as Bacillus subtilis, Mic-
rococcus luteus and Staphylococcus aureus. Moreover, 
we compared the anticancer properties of the same mol-
ecule with naringenin, flavanone and hesperetin on AGS 
(gastric carcinoma), HCT116 (colon carcinoma), HepG2 
(hepatic carcinoma) and HeLa (epithelioid cervix carci-
noma) cancer cell lines.
Results
Expression, purification and spectral analysis of P450 BM3
The sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) analysis of soluble and insolu-
ble fraction of CYP450 BM3 and mutant variants M13 
and M15 showed a protein band of approximate size 
of 119  kDa. Most of the protein was found in insoluble 
fraction. Yet, we have not tried to improve the amount 
of soluble protein using different growth conditions and 
isopropyl-β-D-thiogalactopyranoside (IPTG) concentra-
tions. Simply, the soluble cytosolic fraction was collected 
using Amicon®Ultra-100 device—100,000 NMWL. 
The oxidized forms of the three proteins CYP450 BM3, 
M13 and M15 showed typical spectral properties of 
CYP enzymes with absorption at 420  nm. The sodium 
dithionite reduced spectra of the CYPs showed dimin-
ished absorption maxima in the Soret region. The peak 
maximum in the CO-difference spectra was at 450  nm. 
The Soret shift of proteins CYP450 BM3, M13 and M15 
from 418  nm (Fig.  2a), 419  nm (Fig.  2b), and 420  nm 
(Fig.  2c) to 450  nm, respectively (for the FeII-CO com-
plex) are indicative of native FeII-CO complexes of 
CYPs [36]. The expression yields of protein CYP450 
BM3, M13 and M15 determined from the CO-differ-
ence spectra using an extinction molecular coefficient 
of €450–490  =  91  mM−1  cm−1 were 747.253, 1923.077, 
472.527 nM/L, respectively. We determined the concen-
trations of proteins CYP450 BM3, M13 and M15 using 
the Bradford method to be approximately 4.705, 7.699 
and 7.405 µg/mL, respectively.
In vitro reaction
In vitro reaction of three proteins was carried out with 
twenty different flavonoids (flavonols, flavones, fla-
vanones) and isoflavonoids under identical conditions as 
mentioned in methods. The reaction mixture was ana-
lyzed by high performance liquid chromatography-pho-
todiode array (HPLC-PDA) for the preliminary analysis 
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of hydroxylated products. Out of 20 substrates tested, 
seven flavonoids [naringenin, flavanone, genistein, daid-
zein, biochanin A, apigenin, 3-hydroxyflavone (3-HF)] 
were found to be hydroxylated with M13 and M15 
mutant variants. We were unable to find catalytic activ-
ity of CYP450 BM3 with all of the flavonoids tested. The 
HPLC-PDA analysis also showed higher catalytic activity 
of M13 as a monooxygenase than M15. The compara-
tive conversion percentage of each substrate to products 
with M13 and M15 are presented in Table 1. Each prod-
uct of the reaction was characterized by UV absorbance 
maxima and high-resolution quadruple time-of-flight 
electrospray ionization-mass spectrometry (HR-QTOF 
ESI/MS) which is shown in Table  1 and supplementary 
files. Among flavonoids, the conversion of naringenin 
to hydroxylated derivative (retention time for peak 1 
(tRP1) ~15.426 min, Fig. 3a(iii); calculated mass for molec-
ular formula C15H13O6 for [M  +  H]+ m/z+  ~  289.0712 
for which observed mass [M  +  H]+ m/z+  ~  289.0710, 
λmax: 287 nm) by protein M13 was 15.16 % in comparison 
with 2.82 % by protein M15 (Fig. 3a(iv); Additional file 1: 
Figure S1). Similarly, the conversion of apigenin to the 
product (tRa1 ~ 15.274 min, calculated mass for molecu-
lar formula C15H11O6 for [M + H]+ m/z+ ~ 287.0556 for 
Fig. 1 Structures of the flavonoids used in this study for in vitro reaction using CYP450 BM3 and its variants
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which observed mass [M + H]+ m/z+ ~ 287.0550, λmax: 
247 and 339 nm) was 4.89 % by M13 variant which was 
only 1.14 % with M15 (Additional file 1: Figure S2). Inter-
estingly, protein M15 did not exhibit any catalytic activ-
ity towards 3-HF, however, protein M13 catalyzed 3-HF 
to hydroxylated product (tRh1  ~  17.470  min, calculated 
mass for molecular formula C15H11O4 for [M + H]+ m/
z+  ~  255.0657 for which observed mass [M  +  H]+ m/
z+  ~  255.0734, λmax: 241, 306 and 339  nm) with 4.47  % 
conversion rate (Additional file  1: Figure S3). Further-
more, we were also able to detect two mono-hydrox-
ylated flavanone (tRf2  ~  16.355  min, calculated mass 
for molecular formula C15H13O3 for [M  +  H]+ m/
z+  ~  241.0865 for which observed mass [M  +  H]+ m/
z+ ~ 241.0864, λmax: 224 nm; and tRf3 ~ 16.798 min, calcu-
lated mass for molecular formula C15H13O3 for [M + H]+ 
m/z+ ~ 241.0865 for which observed mass [M + H]+ m/
z+ ~ 257.0857, λmax: 224 nm) as well as di-hydroxylated 
flavanone derivatives (tRf1  ~  11.461  min, calculated 
mass for molecular formula C15H13O4 for [M + H]+ m/
z+  ~  257.0814 for which observed mass [M  +  H]+ m/
z+ ~ 257.0811, λmax: 240, 278 and 339 nm) by M13 with 
conversion rates of 12.26  %, 8.87  % and 9.65  %, respec-
tively (Additional file 1: Figure S4). Likewise, the analysis 
of genistein reaction mixture showed two hydroxylated 
products (tRg1 ~ 14.836 min, calculated mass for molec-
ular formula C15H11O6 for [M  +  H]+ m/z+  ~  287.0556 
for which observed mass [M  +  H]+ m/z+  ~  287.0552, 
λmax: 260  nm; tRg2  ~  15.485, calculated mass for molec-
ular formula C15H11O6 for [M  +  H]+ m/z+  ~  287.0556 
for which observed mass [M  +  H]+ m/z+  ~  287.0569, 
λmax: 268  nm) with both protein variants M13 and 
M15 (Additional file  1: Figure S5). We also found simi-
lar pattern of hydroxylation with another isoflavonoid 
molecule-daidzein. Both the enzymes produced two 
hydroxylated daidzein products having exactly simi-
lar retention time and mass spectra (tRd1  ~  13.683  min, 
calculated mass for molecular formula C15H11O5 for 
[M  +  H]+ m/z+  ~  271.0606 for which observed mass 
[M + H]+ m/z+ ~ 271.0607, λmax: 254 nm; tRd2 ~ 14.369, 
calculated mass for molecular formula C15H11O5 for 
[M  +  H]+ m/z+  ~  271.0606 for which observed mass 
[M +  H]+ m/z+  ~  271.0603, λmax: 257  nm) (Additional 
file  1: Figure S6). However, in the case of biochanin A, 
M13 enzyme not only hydroxylated it (tRb3  ~  17.400; 
calculated mass for molecular formula C16H13O6 for 
[M  +  H]+ m/z+  ~  301.0712 for which observed mass 
[M + H]+ m/z+ ~ 301.0711, λmax: 267 nm) but also dem-
ethylated (tRb2  ~  17.096, calculated mass for molecu-
lar formula C15H11O5 for [M  +  H]+ m/z+  ~  271.0606 
for which observed mass [M  +  H]+ m/z+  ~  271.0600, 
λmax: 260  nm). Moreover, the demethylated derivative 
was further hydroxylated (tRb1  ~  16.376  min, calculated 
mass for molecular formula C15H11O6 for [M + H]+ m/
z+  ~  287.0556 for which observed mass [M  +  H]+ m/
z+ ~ 287.0556, λmax: 268 nm). In contrast, M15 only dem-
ethylated biochanin A in trace amount (Additional file 1: 
Figure S7). In overall, these in vitro results showed that 
CYP450 BM3 variants preferred to catalyze over different 
classes of flavonoids and isoflavonoids. Among several 
flavonoids, we chosenaringenin for further study using 
the variants of CYP450 BM3 because of its higher in vitro 
conversion rate and single reaction product. 
Kinetic parameters of naringenin oxidation by P450 BM3
We used two protein variants M13 and M15 to measure 
kinetic parameters for the hydroxylation of naringenin. 
Protein M15 did not show any or appreciable activities to 
determine kinetic parameters. Only protein M13 showed 
significantly elevated Km and Kcat for the 3′-hydroxyla-
tion reaction with 446  µM and 1.955  s−1, respectively. 
This result indicated that M13 could be used for the bio-
conversion of naringenin into hydroxylated metabolite.
Whole cell biotransformations of naringenin
We used the three recombinant strains harbor-
ing CYP450 BM3, M13 and M15 proteins expressing 
plasmids to check the bioconversion of exogenously 
Fig. 2 CO–binding spectra of protein a CYP450 BM3 wild type, b M13 and c M15. The dotted line denotes the oxidized form, and solid line denotes 
the reduced form
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supplemented naringenin as described in the “Meth-
ods” section. The HPLC-PDA chromatograms of extract 
from the biotransformation reaction of all three E. coli 
strains showed a peak at tR  ~  15.426  min (P1), which 
could be the probable hydroxylated product of nar-
ingenin (tR  ~  16.429  min) at the UV absorbance of 
290  nm (Fig.  3b). These peaks were further analyzed 
by HR-QTOF ESI/MS. The exact mass of naringenin 
standard [M  +  H]+ m/z+ was observed at ∼273.0756 
corresponding to molecular formula C15H13O5 with 
λmax ∼ 286 nm, for which the exact calculated mass was 
∼273.0763 (Additional file 1: Figure S1). The mass spec-
tra displayed the exact mass of hydroxylated product 
P1 [M + H]+ m/z+ ∼ 289.0710 resemble molecular for-
mula C15H13O6 with λmax ∼  287  nm, for with the exact 
calculated mass was ∼289.0712 (Additional file  1: Fig-
ure S1). Besides this product, M15 gene harboring strain 
had additional two new peaks at tR  ~  16.241  min (P2) 
which has exact mass of [M  +  H]+ m/z+  ∼  271.0608 
with λmax ∼  254 and 336 nm corresponding to molecu-
lar formula C15H11O5 for which the calculated mass 
[M + H]+ m/z+ ∼ 271.0606 (Additional file 1: Figure S1), 
and tR ~ 15.274 min (P3) with exact mass of [M + H]+ 
m/z+  ∼  287.0540 with λmax  ∼  247 and 339  nm corre-
sponding to molecular formula C15H11O6 for which the 
calculated mass [M + H]+ m/z+ ∼ 287.0556 (Additional 
file  1: Figure S1). Peak P2 exactly matched with the tR 
of standard apigenin and mass spectra were also simi-
lar (Additional file 1: Figure S2). Thus, this product was 
confirmed to be apigenin while P3 was confirmed to be 
hydroxylated apigenin, which was predicted to be luteo-
lin. This result showed that M15 could be applied for fla-
vonoids compound not only as monooxygenase but also 
as flavone synthases [34]. Three recombinant hosts were 
used for the comparative study of a higher bioconver-
sion of naringenin to the target product with a substrate 
concentration of 50 µM at 48 h. The comparative conver-
sion rate analysis showed the maximum conversion was 
Table 1 The conversion product, HPLC-PDA, HR-QTOF ESI/MS and UV maxima analyses of acceptor substrates in in vitro 
reaction using CYP450 BM3 and its variant proteins M13 and M15
CYP450 BM3 has not shown activity under the test conditions
Substrates Products
















Naringenin 16.429 273.0756 286 Hydroxylated 15.16 2.82 15.426 289.0710 287
Apigenin 16.241 271.0608 254, 336 Hydroxylated 
(a1)
4.89 1.14 15.274 287.0540 247, 339
3‑HF 21.310 239.0702 235, 305 Hydroxylated 
(h1)
4.47 Trace 17.470 255.0734 241, 306, 339
Flavanone 21.645 225.0916 252, 318 Hydroxylated 
(f2)
12.26 Trace 16.355 241.0864 224
Hydroxylated 
(f3)
8.87 Trace 16.798 241.0857 224
Di‑hydroxy‑
lated (f1)
9.65 5.69 11.461 257.0811 240; 278, 339
Genistein 16.622 271.0608 260 Hydroxylated 
(g1)
33.38 1.95 14.836 287.0552 260
Hydroxylated 
(g2)
2.77 1.02 15.485 287.0569 268
Daizein 15.264 255.0656 248 Hydroxylated 
(d1)
14.09 5.37 13.683 271.0607 254
Hydroxylated 
(d2)
4.81 1.67 14.369 271.0603 257
Biochanin A 19.444 285.0762 260 Hydroxylated 
(b3)
27.73 17.400 301.0711 267
De‑methylated 
(b2)





2.47 Trace 16.376 287.0556 268
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34.48 % by M13, followed by M15 and CYP450 BM3 with 
16.11  % and 2.47  %, respectively (Fig.  4a). These results 
further indicated that M13 harboring strain could be 
a good recombinant host system for the production of 
hydroxylated product from naringenin.
Bioconversion with different naringenin concentration
To study the optimal substrate concentration, we sepa-
rately supplied the various concentrations of naringenin 
(50, 100, 200, 300, 500, 800 µM) to biocatalysis reaction 
system with M13. The cell growth and substrate conver-
sion were monitored at 12  h intervals. The maximum 
bioconversion of naringenin showed 43.73 % at 48 h with 
OD600 ~ 2.80 when 100 µM of naringenin was added in 
the biotransformation reaction. Even though the con-
version decreased when a higher amount of naringenin 
was supplied at the same time (Fig. 4b), the growth rate 
of the cell was steady and stable (Fig.  4c). These results 
indicated that the high concentration of naringenin could 
be a reason for inhibition of the hydroxylation product in 
E. coli whole cell.
Scale‑up by fermentation
We cultured the recombinant strain M13 in a 3-L fermen-
tor as described in the materials and methods, where we 
supplemented an optimized concentration of naringenin 
(100 µM, ~81.7 mg in 3 L) and glucose 2 %. The tempera-
ture of the fermentor was maintained at 28 °C while pH 
was 7.4 throughout the process. The culture medium 
was harvested at regular time interval of 12  h and ana-
lyzed by HPLC-PDA to monitor the conversion of nar-
ingenin to hydroxylated product. The added naringenin 
was not completely converted until 48 h. Only 46.95 µM 
(~40.7 mg) of hydroxylated naringenin was produced as 
a maximal yield of the approximately 49.81 % bioconver-
sion rate of the substrate (Fig. 4d).
Structural elucidation of hydroxylated naringenin
We analyzed the structures of naringenin standard and 
purified hydroxylated product by 1H-NMR as well as 
13C-NMR at 700 MHz in DMSO-d6. The 1H-NMR spec-
trum of hydroxylated naringenin showed the absence of 
proton signal at δ = 6.8 ppm (m) for C-3′. Moreover, we 
Fig. 3 HPLC‑PDA analysis of a in vitro hydroxylation reaction mixture and b whole cells bioconversion of naringenin. (i) control reaction of narin‑
genin using E. coli BL21 (DE3); (ii) hydroxylation of naringenin with CYP450 BM3, (iii) M13 and (iv) M15, respectively
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observed an upfield shift at δ = 146.18 ppm of the C-3′ 
of hydroxylated product compared to the same carbon 
of naringenin at δ = 115.63 ppm, and an accompanying 
downfield shift of the resonances of the adjacent carbons 
C-4′ at δ  =  145.65  ppm and δ  =  158.20  ppm, respec-
tively (Table 2; Additional file 1: Figures S8, S9). By these 
analyses, we confirmed naringenin, which previously has 
been found in citrus plants [37]. Similarly, we identified 
3′,4′,5,7-tetrahydroxyflavanone as a 3′-OH hydroxylated 
derivative of naringenin, which is known as eriodictyol. 
The NMR data were consistent with the previously pub-
lished results [38].
Antibacterial activities of compounds
We determined the antibacterial activity of flavanone, 
hesperetin, naringenin, and eriodictyol by disc diffusion 
assays against five different human pathogens including 
three Gram-positive (B. subtilis, M. luteus and S. aureus) 
and two Gram-negative (P. aeruginosa and E. cloacae) 
bacteria in comparison with kanamycin. Additional file 1: 
Table S1 summarizes the results. Flavanone, hespere-
tin and naringenin did not display antibacterial activity 
against the tested Gram-positive bacteria as compared 
with eriodictyol and kanamycin when 10  µL of 50  mM 
concentration was applied in disc diffusion. However, the 
results also showed that flavanone and hesperetin exhib-
ited very low antibacterial activity against Gram-negative 
bacteria such as P. aeruginosa and E. cloacae. Interest-
ingly, eriodictyol showed the highest activity in inhibiting 
M. luteus, followed by S. aureus and was also equipo-
tent against B. subtilis, with zone of inhibition values of 
22.5 ± 0.47, 16 ± 0.16 and 11 ± 0.12 mm, respectively. 
Moreover, we detected the zone of inhibition against M. 
luteus by eriodictyol was 2.5 times higher than kanamy-
cin (Additional file 1: Table S1). The results revealed that 
the modification of naringenin at the C-3′ position could 
be beneficial for the enhancement of antibacterial activity 
against particular Gram-positive bacteria.
Anticancer activities of compounds
We carried out MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) colorimetric assay 
to evaluate the potential anticancer effects of narin-
genin, flavanone, hesperetin and eriodictyol on four dif-
ferent cancer cell lines of AGS, HCT116, HepG2, and 
HeLa. The cell viability data showed that naringenin and 
Fig. 4 a Comparison of hydroxylated naringenin production from CYP450 BM3 wild type, M13 and M15 in M9 minimal medium supplemented 
with 2 % glucose at 48 h of incubation with 50 µM naringenin. b The substrate concentration optimization of naringenin (50–800 µM) in biotrans‑
formation. c Cell growth at OD600 nm while using various concentrations of naringenin during biotransformation. d The scale‑up production of 
hydroxylated naringenin in 3‑L fermentation at different time intervals. Standard deviations were calculated from the results of three independent 
experiments
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hesperetin did not have anticancer activity against all cell 
lines, whereas eriodictyol exhibited the most effective 
anticancer activity against four cell lines, which was fol-
lowed by flavanone (Fig. 5). The cell viability data of AGS, 
HCT116, Hela, and HepG2 cell lines indicated 100  µM 
of eriodictyol reduced the cell viability by approximately 
15.18 %, 15.28 %, 49.30 %, and 24.94 % (p < 0.01), respec-
tively, as compared to control. The 50 % inhibitory con-
centration (IC50) values of eriodictyol were 19.64, 35.85 
and 37.72 µM in AGS, HCT116 and HepG2, respectively. 
In addition, flavanone inhibited HCT116 and Hela cell 
lines with IC50 values of 48.10 and 33.40 µM, respectively 
(Additional file  1: Table S2). These results suggest that 
treatment with eriodictyol and flavanone significantly 
reduces the cell viability of HCT116 and Hela cell lines 
in a dose-dependent manner. This is the first report of 
activity of both compounds against HCT116 and Hela 
cell lines.
Modeling and docking of naringenin to P450 BM3 and its 
variants
We selected a protein crystal structure previously 
resolved (PDB ID: 1BU7) from B. megaterium as tem-
plate to build the protein models of M13 and M15 using 
Accelrys Discovery Studio 3.5 software (Accelrys Inc., 
San Diego, CA). Figure  6 presents three-dimensional 
(3D) structure of the heme-Fe-dependent monooxyge-
nase domain of each protein. To the models, following 
active-site optimization, molecular dynamics were used 
to dock naringenin. The study of all docked conforma-
tions of naringenin in the three CYP450 BM3 models 
showed that the spatial orientation of the active sites of 
protein M13 is somewhat different from that of protein 
M15 and CYP450 BM3. The C-3′ position of naringenin 
was closer to the Fe of heme of the M13 and M15 than to 
CYP450 BM3 model. The distance between Fe and C-3′ 
was 4.297, 5.570 and 14.318 Å (Fig.  6) with M13, M15 
and CYP450 BM3, respectively. This in silico docking 
result is consistent with our hydroxylation reaction elu-
cidating the higher catalytic activity of M13 with narin-
genin and other flavonoids.
Discussion
The hydroxylation of secondary metabolites is one of the 
main modifications that have a profound impact on phys-
ical as well as biological changes in the molecules [39]. In 
this study, we studied expanded substrates flexibility of 
CYP450 BM3 towards flavonoid aglycones. The oxida-
tive hydroxylation of flavonoids was not shown by wild 
type CYP450 BM3, however, both engineered variants of 
the same enzyme namely M13 and M15 accepted various 
flavonoids and isoflavonoids as substrates for hydroxyla-
tion which includes flavone (apigenin), flavanones (nar-
ingenin, flavanone), flavonol (3-HF), and isoflavonoids 
(genistein, daidzein, biochanin A) (Table 1). These results 
suggest that in  vitro enzymatic synthesis using CYP450 
Table 2 Comparison of 1H-NMR and 13C-NMR of naringenin standard with hydroxylated naringenin (eriodictyol)
s singlet, d doublet, dd doublet of doublet, m multiplet
Carbon no. Naringenin Hydroxylated product (Eriodictyol)
1H NMR 13C NMR 1H NMR 13C NMR
2 5.44 (dd, J = 12.8, 3.0 Hz) 78.90 5.38 (dd, J = 12.5, 3.1 Hz) 78.92
3‑trans 3.27 (dd, J = 17.1, 12.8 Hz) 42.44 3.19 (dd, J = 17.1, 12.5 Hz) 42.54
3‑cis 2.69 (dd, J = 17.1, 3.1 Hz) 42.44 2.68 (dd, J = 17.1, 3.2 Hz) 42.54
4 196.88 196.84
4a 102.24 102.26
5‑OH 12.16 (s) 163.96 12.15 (s) 163.94
6 5.89 (s) 96.25 5.88 (m) 96.21
7‑OH 10.78 (s) 167.11 10.80 (s, 1H) 167.10
8 5.89 (s) 95.43 5.88 (m) 95.41
8a 163.41 163.37
1′ 129.32 129.91
2′ 7.32 (m) 128.82 6.88 (s) 115.79
3′ 6.80 (m) 115.63 146.18
3′‑OH 9.05 (d, J = 34.2 Hz)
4′‑OH 9.59 (s) 158.20 9.05 (d, J = 34.2 Hz) 145.65
5′ 6.80 (m) 115.63 6.75 (s) 114.81
6′ 7.32 (m) 128.82 6.75 (s) 118.41
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BM3 variants opened up prospects for the synthesis of 
hydroxylated flavonoids, which could be applied to other 
substrates as well, to generate libraries of compounds.
After in  vitro reactions, we applied all three enzymes 
for whole cell catalysis. Interestingly, CYP450 BM3 exhib-
ited activity towards naringenin with very low conversion 
rate. Two mutant proteins M13 and M15 overexpress-
ing plasmid harboring strain showed higher catalytic 
efficiency with naringenin than wild type CYP450 BM3 
harboring strain (Fig. 3). One possible reason to explain 
the lower hydroxylation activity of CYP450 BM3 could 
be the long-distance between possible oxidizable car-
bons of flavonoids and the heme iron with its ferric rest-
ing state in the enzyme [40] as depicted in molecular 
modelling and docking of naringenin. For example, the 
average distance C-3′ of naringenin to the Fe of heme of 
CYP450 BM3 enzyme in the orientation of 3′-hydroxyla-
tion is 14.318 Å; whereas, the distances were 4.297 and 
5.570  Å with M13 and M15, respectively (Fig.  6). The 
variation in distance among the three enzymes could be 
because of the substitution of several key amino acids of 
CYP450 BM3 wild type while generating M13 and M15. 
These substituted amino acids were reported to influ-
ence either the substrate selectivity or activity or both 
of CYP450 BM3. For example, the arginine residues at 
position 47 (ARG47; R47) are believed to be important 
for entrance of the substrate to the channel, and to con-
trol substrate accessibility to the binding pocket [9]. The 
amino acid leucine at position 86 (LEU86; L86) is posi-
tioned near one of the heme propionate groups, and 
could affect the heme properties leading to increase of 
enzyme activities [41]. Phenylalanine 87 (PHE87; F87) is 
another key residue that is highly conserved. Its muta-
tion could affect activity and stereo-selectivity or regio-
selectivity of enzyme [42]. Similarly, glutamic acid 267 
(GLU267; E267) is called the solvent channel, which pre-
vents bulk amount of solvent from entering the active site 
[41]. It is also likely that the substituted key amino acid in 
the wild type protein could cause the change of CO-dif-
ference spectra of M13 and M15. As spectrophotometric 
Fig. 5 Effects of naringenin, eriodictyol, hesperetin and flavanone on the growth of various cancer cell lines. Cell viability was measured using MTT 
colorimetric assay. Standard deviations were calculated from the results of three independent experiments
Page 10 of 15Chu et al. Microb Cell Fact  (2016) 15:135 
evidence for the presence of an active form of CYP450, 
a peak at 450 nm was observed from a CO-induced dif-
ference spectrum in all the proteins. However, the CO-
difference spectra of M13 and M15 changed by 1923.077, 
472.527 nM/L, respectively, in comparison with wild type 
747.253 nM/L (Fig. 2).
One emerging application of CYP450s for the pharma-
ceutical industry is the generation of large amounts of 
metabolite drug. However, one concern encountered when 
applying an in  vitro enzymatic synthesis approach medi-
ated by CYP450 monooxygenase is the cost of cofactor 
NAD(P)H. These cofactors are not economically feasible, 
and unstable in solution [43]. Although the in vitro reac-
tion mixture used a NADPH regenerating system which 
consists of glucose-6-phosphate dehydrogenase, glucose-
6-phosphate, NADP+, the cost of the reaction is higher 
and reaction yield is relatively low. For instance, M13 was 
found to convert naringenin, flavanone, genistein, daid-
zein, apigenin, and 3-HF to their respective hydroxylated 
derivatives with conversion rate of 15.16, 30.78, 36.15, 18.9, 
4.89 and 4.47 %, respectively, in the in vitro reaction. While 
M15 exhibited much lower conversion of those substrates 
than M13 and CYP450 BM3 did not show any conversion 
of flavonoids (Table 1). Since, there was very low conver-
sion rate for each substrate; we sought to develop a whole 
cell approach using the recombinant M13 strain to modify 
one of the substrates, naringenin for the hydroxylation and 
production of eriodictyol utilizing endogenous NADPH 
from E. coli cell cytosol. In the whole cell biocatalysis sys-
tem, production of eriodictyol increased by up to 34.48 % 
(Fig. 4a). This result indicated that the recombinant M13 
strain not only led to the reduction of the cost of reac-
tion but also increased the efficiency of the regio-selective 
hydroxylation of naringenin. The recombinant M13 strain 
was further applied for the large-scale production of eriod-
ictyol in a 3-L fermentor supplementing 100 µM of narin-
genin. The bioconversion experiment produced 46.95 µM 
(~40.7  mg) of eriodictyol in 48  h incubation (Fig.  4b). 
These data indicate that the system’s efficiency increased, 
and could be applicable to high-scale biotransformation. 
Moreover, metabolic engineering and other approaches 
are warranted to further enhance the production, and 
apply to industrial production of the target molecule. For 
example, overexpression of glucose-6-phosphate dehydro-
genase (zwf) to redirect the glycolysis flux to the pentose 
phosphate pathway [44, 45] or the using a stoichiometric-
based model to identify combination of gene knockouts 
in E. coli, resulted in significantly improved availability of 
NADPH in connection to the target production pathway 
[46].
Another interesting result we observed during this 
experiment was generation of apigenin in whole cell bio-
transformation of naringenin while using the recombi-
nant M15 strain. Instead of production of hydroxylated 
derivative, we were able to detect apigenin and its hydrox-
ylated derivative in the reaction mixture (Fig.  3). Thus, 
the modification reaction is divided via two paths, the 
formation of eriodictyol from naringenin which proceeds 
through hydroxylation directed at C-3′ of B-ring; and 
M15, which is capable of functioning as flavone synthase 
on the formation of apigenin from naringenin [34]. How-
ever, detailed study on the formation of apigenin and its 
hydroxylated derivative from naringenin are essential and 
which we will be carried out in the near future using M15.
We also accessed the antibacterial and anticancer 
activities of three flavanones and eriodictyol in this 
study. Three Gram-positive bacteria M. luteus, B. subtilis, 
and S. aureus were sensitive with eriodictyol, while two 
Gram-negative bacteria P. aeruginosa and E. cloacae were 
Fig. 6 Molecular modeling and docking of naringenin. a CYP450 
BM3 wild type (Protein Data Bank code: 1BU7), b M13 and c M15. 
The average distance from naringenin C‑3′ to the Fe of heme in the 
orientation of 3′‑hydroxylation is 14.318, 4.297 and 5.570 A˚ for CYP 
BM3, M13 and M15, respectively
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susceptible with flavanone and hesperetin. Interestingly, 
eriodictyol showed higher antibacterial activity against 
M. luteus than an aminoglycoside antibiotic, kanamycin 
(Additional file 1: Table S1). The possible reason behind 
the antibacterial activity of eriodictyol could be the inter-
calation or formation of hydrogen bond between B ring 
of the eriodictyol and stacking between nucleic acid 
bases, which lead to the inhibition of DNA and RNA syn-
thesis in bacteria [47]. Among four compounds, eriodic-
tyol and flavanone showed the most potential anticancer 
activity against cell lines (Fig.  5; Additional file  1: Table 
S2). Previous study reported that eriodictyol inhibited 
the production of TNF-α and IL-β in kidney tissues, and 
inhibited the production of blood urea nitrogen (BUN), 
as well as up-regulating the expression of nuclear fac-
tor erythroid 2-related factor 2/Heme oxygenase-1 and 
inhibiting of cisplatin-induced nuclear factor-kappa 
B activation in kidney tissues [48]. In addition to those 
activities, we accessed the activity of eriodictyol against 
HCT116 and Hela cell lines for the first time. These 
results collectively open up the possible benefits of 
hydroxylation of naringenin at the C-3′ position to gen-
erate promising lead molecule against various cancer cell 
lines as well as Gram-positive bacteria.
Conclusions
In conclusion, the present study shows that protein engi-
neering of CYP450 BM3 enzyme is able to expand the 
substrate flexibility of enzyme towards the flavonoid 
group of compounds. Moreover, the study also demon-
strated the application of engineered protein in whole 
cell biocatalysis for the production of valuable molecules 
by a simple fermentation approach, which is very easy to 
scale up, and cheaper than other approaches. As a proof 
of study, we used naringenin as a substrate for hydroxyla-
tion in in vivo system and demonstrated the production 
of eriodictyol in a lab scale fermentor. Though the pro-
duction of the target hydroxylated molecule was low, the 
application of metabolic engineering and synthetic biol-
ogy tools will certainly help to enhance the production of 
eriodictyol from naringenin. This is the first report of eri-
odictyol being produced from naringenin using recombi-
nant CYP450 BM3 and its variants from B. megaterium. 
We believe that this study opens up an approach for the 
production of important hydroxylated compounds of 
various polyphenols in an industrial scale using CYP450 
BM3 variant which is restricted to fatty acids.
Methods
Chemicals and reagents
β-Nicotinamide adenine dinucleotide phosphate sodium 
salt hydrate in oxidized form was bought for biochemi-
cal research from Tokyo Chemical Industry Co., Ltd 
(Kita-Ku, Tokyo, Japan). HPLC grade acetonitrile and 
water were purchased from Mallinckrodt Baker (Phil-
lipsburg, NJ, USA). All the flavonoids and chemicals used 
were purchased from Sigma–Aldrich Chemical Co. (St. 
Louis, MO, USA).
Plasmids, microorganisms and media
The plasmid pCW(Ori+)-CYP450 BM3 wild type, 
pCW(Ori+)-mutant 13 (M13) and pCW(Ori+)-mutant 
15 (M15) have previously been constructed [13]. Each 
mutant carries the following amino acid substitution 
relative to wild type CYP450 BM3: M13 (R47L/L86I/
F87V/L188Q) [49] and M15 (R47L/E64G/F87V/E143G/
L188Q/E267V) [13]. We transformed these plasmids into 
E. coli BL21 (DE3) (Stratagene, USA) using standard pro-
cedures. The 5× M9 salts stock solution contained 30 g 
Na2HPO4, 15  g KH2PO4, 2.5  g NaCl, 5  g NH4Cl, 0.24  g 
MgSO4, 0.01 g CaCl2 and 20 g glucose was used to pre-
pare 1× M9 minimal medium for bacterial culture when 
needed.
Protein expression and purification of P450 BM3
We cultured the recombinant strains in 5 mL Luria–Ber-
tani (LB) medium supplemented with ampicillin (100 μg/
mL) at 37  °C, 180  rpm for 6  h. For protein overexpres-
sion, the pre-inoculum (200  µL) was transferred into a 
250 mL shaking flask containing 50 mL 1× M9 minimal 
medium supplemented with ampicillin and incubated 
at 37  °C, 180  rpm. When the optical density at 600  nm 
(OD600 nm) reached 0.8, the protein expression was 
induced with 0.5 mM final concentration of isopropyl-β-
d-thiogalactopyranoside (IPTG). To the culture, 1  mM 
δ-aminolevulinic acid hydrochloride (δ-ALA) was added 
and incubated for 36 h at 28 °C. The cells were harvested 
by centrifugation at 842×g for 15 min, and washed twice 
with 50  mM phosphate buffer pH 7.4 containing 10  % 
glycerol (PG buffer) for two times. The cells were sus-
pended in 1 mL of the same buffer containing 1 mM dithi-
othreitol (DTT) and 1 mM phenylmethylsulfonyl fluoride 
(PMSF). The cells were lyzed by sonication using a Son-
osmasher (2 × 1 min, output control 5, 50 % duty cycle; 
Sonicator, Heat Systems, Ultrasonic, Inc.). Following cen-
trifugation at 13,475×g for 30  min at 4  °C, the resulting 
soluble and insoluble protein fractions were analyzed by 
12 % sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS–PAGE). We collected the soluble cytosolic 
fraction using Amicon®Ultra 50  mL filters (Millipore, 
100,000 K NMWL device; Milford, MA, USA) and stored 
it in PG buffer at −20 °C until the activity assay.
Determination of protein concentration
We determined CYP450 BM3 protein and variants (M13 
and M15) content as described by Omura and Sato [50] 
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using a Shimadzu 1601PCs spectrophotometer (Tokyo, 
Japan). The content of protein CYP450 BM3 was cal-
culated from the spectral difference of extinction CO-
efficient at 450 and 490  nm of € =  91  mM−1cm−1. The 
protein CYP450 BM3 content (nmol) = [(absorbance dif-
ference ×  1000)/91] dilution factor. We determined the 
protein concentration by Bradford method using bovine 
serum albumin as the reference standard [51].
In vitro reaction condition
We carried out 250  µL reactions using the protein 
CYP450 BM3, M13, M15 and 0.5 mM substrate in potas-
sium phosphate buffer (100  mM, pH 7.4) and 10  mM 
MgCl2·6H2O. The reaction was incubated for 15  min at 
37  °C with individual substrates naringenin, flavanone, 
flavone, chrysin, luteolin, diosmetin, baicalein, 7,8-dihy-
droxy flavone, morin, genistein, daidzein, biochanin A, 
kaempferol, quercetin, fisetin, and myricetin  in order 
to investigate the substrate specificity of the enzyme 
(Fig.  1). A NADPH regenerating system consisting of 
glucose-6-phosphate-dehydrogenase (0.5  U), glucose-
6-phosphate (10  mM), and NADP+ (0.5  mM) was then 
added to the reaction mixture and incubated for 30 min 
at 37 °C with shaking. The reaction was stopped by add-
ing a double volume of chilled ethyl acetate, followed by 
vigorous shaking for 30 min, and centrifuged at 13,475×g 
for 10  min. The ethyl acetate organic layer was col-
lected and concentrated to dryness by the evaporation 
of excess solvent. The samples were dissolved in 250 µL 
methanol, and analyzed by high performance liquid 
chromatography-photodiode array (HPLC-PDA) and 
high-resolution quadruple time-of-flight electrospray 
ionization-mass spectrometry (HR-QTOF ESI/MS). The 
conversion percentage of each substrate was determined 
after integrating product and substrate peaks. For quan-
tification of flavonoids, we created a calibration curve of 
authentic substrate using 10, 25, 50, 100 and 200 μg/mL 
concentrations.
Kinetics measurement for naringenin oxidation reactions
We determined the kinetic parameters of M13 and M15 
proteins by using reaction mixtures containing variable 
amounts of naringenin (from 0.05 to 2  mM) in potas-
sium phosphate buffer (100  mM, pH 7.4) consisting of 
10  mM MgCl2·6H2O at 37  °C. We analyzed the prod-
ucts by HPLC-PDA and the Km and Vmax values by the 
Lineweaver–Burk plotting method.
Whole cell biotransformation of naringenin
We precultured the CYP450 BM3, M13 and M15 strains 
in 5  mL LB liquid medium with ampicillin, and incu-
bated them at 37  °C with shaking at 180  rpm for about 
6 h. For whole cell reaction, 200 µL of pre-inoculum was 
transferred into 250  mL flask containing 50  mL of 1× 
M9 minimal medium with appropriate antibiotic. The 
cells were incubated in shaking incubator at 37 °C. When 
the OD600 reached 0.8, the culture was induced with 
0.5 mM final concentration of IPTG. 1 mM δ-ALA was 
also added and incubated for 12 h at 28 °C. To the same 
culture, standard naringenin dissolved in 10 % dimethyl 
sulfoxide (DMSO) was supplemented at a final concen-
tration of 50  µM and extended to incubate at 28  °C for 
60 h. Every 12 h, we collected 500 µL of culture, extracted 
and analyzed by HPLC-PDA.
Scale‑up of whole‑cell biocatalyst system in a fermentor
For large scale biotransformation and production of 
hydroxylated naringenin, we carried out fermentation in 
3 L of 1× M9 minimal media under previously reported 
conditions [52] using recombinant strain harboring M13 
gene overexpressing plasmid. To this induced culture 
100 µM of naringenin was added for biotransformation. 
The culture was supplied with 20 mL sterile glucose solu-
tion (600 g/L) for every hour until 36 h after the start of 
feeding of naringenin. We took samples at every 12  h 
intervals until 48  h for the quantification of product 
formation.
Analytical methods
We obtained the crude extract of compound after extract-
ing culture broth with double volume of ethyl acetate 
(v/v = 2:1) in Soxhlet extractor. The mixture was shook 
for 12  h at room temperature. Then, Soxhlet extractor 
was kept still, and stood until separated into two layers. 
Ethyl acetate organic fraction was taken and dried by 
freezing rotary evaporator. The product formation was 
analyzed by HPLC-PDA using a reversed-phase column 
(Mightysil RP–18 GP 250–4.6 (5  µm), Kanto Chemi-
cal, Japan) at UV absorbance of 290  nm. The binary 
mobile phases were composed of solvent A (0.05 % trif-
luroacetic acid (TFA) in HPLC-grade water) and solvent 
B (100  % acetonitrile, CH3CN). The total flow rate was 
maintained at 1 mL/min for a 30 min. The percentage of 
solvent B used was as follows: 0–20  % (0–5  min), 50  % 
(5–10 min), 70 % (10–15 min), 90 % (15–20 min), 10 % 
(20–25 min), 10 % (25–30 min). The purification of com-
pounds was carried out by preparative HPLC (Shimadzu, 
Tokyo, Japan) with C18 column (YMC–Pack ODS-AQ 
(150  ×  20  mm I.D., 10  µm) connected to a UV detec-
tor at a UV absorbance of 290 nm using a 36-min binary 
program with CH3CN 20 % (0–5 min), 40 % (5–10 min), 
40 % (10–15 min), 90 % (15–25 min), 90 % (25–30 min) 
and 10 % (30–36 min) at a flow rate of 10 mL/min. The 
HR-QTOF ESI/MS analysis was performed in positive 
ion mode using an ACQUITY (UPLC, Waters Corp., Bill-
erica, MA, USA) column coupled with a SYNAPT G2-S 
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(Water Corp.). For nuclear magnetic resonance (NMR) 
analysis of the purified product, compounds were dried, 
lyophilized, and dissolved in dimethyl sulfoxide (DMSO)-




To evaluate the biomedical application of flavanone, 
hesperetin, naringenin and eriodictyol as a antibacterial 
agent, we employed the paper disc diffusion method on 
Mueller–Hinton agar (MHA) plates using kanamycin as 
antibacterial agent control. Three Gram-positive bac-
teria Staphylococcus aureus subsp. aureus KCTC 1916, 
Bacillus subtilis KACC 17047, Micrococcus luteus KACC 
13377, and two Gram-negative bacteria Pseudomonas 
aeruginosa KACC 10232 and Enterobacter cloacae subsp. 
dissolvens KACC 13002 were used. The inocula contain-
ing 107 colony forming units (CFU)/mL were spread on 
MHA plates for bio-assay. Sterile filter paper discs (6 mm 
in diameter) containing 10  µL of 50  mM compounds 
were placed on the surface of the inoculated agar plates. 
The plates were incubated at 37  °C for 12  h. We tested 
each compound in triplicate, and measured the zone of 
inhibition in millimeter diameter [53].
Anticancer activities
To evaluate the pharmaceutical potential of naringenin, 
eriodictyol, flavanone and hesperetin as a chemothera-
peutic agent for cancer treatment, we used various can-
cer cell lines consisting of AGS, HCT116, HepG2 and 
HeLa in Roswell Park Memorial Institute 1640 medium 
(Invitrogen, Grand Island, NY, USA) containing 10  % 
fetal bovine serum (FBS, Invitrogen). All cells were main-
tained at 37 °C in a humidified 5 % CO2 incubator. For cell 
growth assay, cells seeded at 2 × 103 cell/well in 96-well 
plates (SPL Life Sciences, Gyeonggi, Korea) were treated 
with each compound in serial dilution (100, 50, 25, 12.5, 
6.25, 3.125 μM) for 72 h. We measured cell growth using 
a MTT colorimetric assay [54].
Molecular modeling and docking of naringenin in P450 
BM3 and its mutants
We selected CYP450 BM3 protein template (Protein 
Data bank [PDB] ID: 1BU7; crystal structure resolved at 
1.65 Å) from B. megaterium to build the model with pro-
tein M13 and M15 using Accelrys Discovery Studio v.3.5 
(2013) (DS 3.5) (Accelrys, San Diego, CA, USA). The con-
struction and validation of protein M13 and M15 models 
were carried out as previously described [55]. Naringenin 
was docked to wild type protein, and the validated mod-
els of protein M13 or M15 using the “Ligand-Fit” proce-
dure implemented in DS 3.5. The conformations of each 
ligand were fitted in the binding cavity of protein with a 
grid-based energy function [56]. We finally selected the 
most suitable docking mode for naringenin with a high 
score from the consensus scoring function to find the dis-
tance between heme core and naringenin.
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